New combo therapy aims to wipe out hidden myeloma cells
Disease control
Not yet recruiting
This phase 3 trial tests whether a new drug combination (belantamab mafodotin plus standard drugs) works better than the current standard (daratumumab plus standard drugs) for people newly diagnosed with multiple myeloma who cannot have a bone marrow transplant. The study will en…
Phase: PHASE3 • Sponsor: PrECOG, LLC. • Aim: Disease control
Last updated May 13, 2026 16:00 UTC